Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ:TSHA
TSHA Stock Chart & Stats
$4.64
-$0.08(-4.26%)
At close: 4:00 PM EST
$4.64
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$1.05 - $6.02
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.31M
Market Cap
$1.24B
Enterprise Value$878.55M
Total Cash (Recent Filing)$297.34M
Total Debt (Recent Filing)$69.08M
Price to Earnings (P/E)―
Beta2.74
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding273,919,370
10 Day Avg. Volume2,212,567
30 Day Avg. Volume2,312,142
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.05
Price to Sales (P/S)51.93
P/FCF Ratio-5.30
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue139.23
Enterprise Value/Gross Profit145.84
Enterprise Value/Ebitda-8.90
Forecast
1Y Price Target
$11.83Price Target Upside154.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$4.46M
Bulls Say, Bears Say
Bulls Say
Clinical SafetyEarly clinical data show proof of concept with no signs of toxic MeCP2 overexpression, bolstering confidence in the gene therapy's safety profile.
Natural History EvidenceComprehensive natural history analyses indicate limited spontaneous milestone gains in the targeted patient group, supporting the planned statistical design's ability to detect a true treatment effect.
Regulatory ValidationRegulatory reviewers endorsed the trial's statistical approach and judged powering calculations to be solid, supporting the study's credibility and regulatory acceptability.
Bears Say
Data RobustnessReliance on a pre-printed natural history analysis that has not completed peer review introduces uncertainty about the strength and validation of findings underpinning the trial design.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $1.05 and its highest was $6.02 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $1.24B.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is May 20, 2026 which is in 75 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Currently, no data Available
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 273,919,370 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.83 (154.96% Upside)
$11.83 (154.96% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
184.66%
12-Months-Change
Fundamentals
Return on Equity
-64.93%
Trailing 12-Months
Asset Growth
75.65%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and regulatory progress with TSHA-102, including Breakthrough Therapy designation and strong clinical data, as well as strategic regaining of rights. However, this progress is tempered by increased expenses and net loss. Overall, the sentiment of the call leans positive due to the promising clinical results and regulatory advancements.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$11.83
▲(154.96% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
12.88% Insiders
9.26% Mutual Funds
0.89% Other Institutional Investors
65.09% Public Companies and Individual Investors